Zobrazeno 1 - 10
of 70
pro vyhledávání: '"L O Carreras"'
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:1-4
Many investigators have been intrigued by the paradoxical association of a circulating anticoagulant, first called lupus anticoagulant by Feinstein and Rapaport [1], with a tendency to develop thrombosis, as initially described by Walter Bowie [2]. W
Autor:
L O Carreras, Gonzalo Pombo, Ricardo Forastiero, Yolanda Adamczuk, M. E. Martinuzzo, Graciela S Cerrato, Maria Luisa Iglesias Varela
Publikováno v:
Thrombosis Research. 104:317-324
Factor V Leiden (FVL) and the prothrombin 20210A (PT-20210A) variant are well-known risk factors for venous thromboembolism (VT). The thermolabile variant (TT) of the methylenetetrahydrofolate reductase (MTHFR) gene, and homozygosity for the 4G allel
Publikováno v:
British Journal of Haematology. 114:845-851
Recent studies have shown that patients with antiphospholipid antibodies (aPL) have increased lipid peroxidation. We evaluated the urinary excretion of 11-dehydro thromboxane B2 (11-DH-TXB(2) and isoprostane F(2alpha)III (IPF(2alpha)III), reflecting
Autor:
G Tsariktsian, Ricardo Forastiero, L O Carreras, M M Sturno, B. Alonso, M. E. Martinuzzo, G F de Larrañaga
Publikováno v:
Lupus. 9:594-600
Antiphospholipid antibodies (aPL) have been reported not only in autoimmune disorders but also in various infectious diseases. Accumulating evidence indicates that b2glycoprotein I (b2GPI) and prothrombin are the main proteins to which autoimmune aPL
Publikováno v:
Thrombosis Research. 96:19-25
Alloimmune antiphospholipid antibodies react with phospholipids and are an epiphenomenon of an infectious disease. Most autoimmune antiphospholipid antibodies recognise phospholipid-protein complexes or proteins, such as beta2 glycoprotein I or proth
Publikováno v:
Blood Coagulation & Fibrinolysis. 3:765-772
We studied the natural inhibitors (NI) of blood coagulation and fibrinolysis in 50 patients with lupus anticoagulant (LA), in order to identify possible alterations of these NI, that could favour thrombotic manifestations. We found no statistically s
Publikováno v:
Clinical and experimental rheumatology. 21(2)
Some studies have previously suggested the involvement of antibodies directed against CD36 (anti-CD36) in the pathogenesis of thrombosis. The aim of this study was to evaluate the prevalence of anti-CD36 in patients with antiphospholipid antibodies (
Autor:
M E, Martinuzzo, G F, de Larrañaga, R R, Forastiero, Y, Pelegri, M H, Fariña, B S, Alonso, L C, Kordich, L O, Carreras
Publikováno v:
Clinical and experimental rheumatology. 20(4)
To evaluate plasma levels of markers of platelet, endothelial cell and blood coagulation activation in leprosy patients with or without antiphospholipid antibodies (aPL) and to compare them to those found in patients with antiphospholipid syndrome (A
Publikováno v:
British journal of haematology. 114(4)
Recent studies have shown that patients with antiphospholipid antibodies (aPL) have increased lipid peroxidation. We evaluated the urinary excretion of 11-dehydro thromboxane B2 (11-DH-TXB(2) and isoprostane F(2alpha)III (IPF(2alpha)III), reflecting
Publikováno v:
Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 12(6)
Chronic thromboembolic pulmonary hypertension (CTE-PH) is an infrequent cause of pulmonary hypertension that develops in 0.1-0.2% of patients who survive after an acute venous thromboembolic event. According to the largest series so far reported, 15-